News & Resources

Alleviating Cancer’s Financial Toxicity in the US Requires National Policy Changes

Financial toxicity following cancer treatment in the United States is a growing concern. Even small increases in out-of-pocket costs are associated with treatment nonadherence for some families, and may contribute to ever-widening social disparities in care and survival of patients with cancer. Patients from racial and ethnic minority groups are more likely to lack insurance and suffer from adverse financial consequences. In a recent Viewpoint article in JAMA Oncology, Dr Cathy J. Bradley et al advocated for a coordinated nationwide policy approach that supports clinicians and patients while reducing the financial burden associated with cancer treatment.

At the community level, it has been proposed that medical practices provide navigation to help patients and caregivers connect to resources. However, widespread adoption of patient navigators is limited by the lack of a sustained financial model for reimbursement. Another recommendation is for clinicians to integrate cost discussions into shared treatment decisions. Although many believe this to be an effective approach, few practices are doing it, for multiple reasons. Costs are rarely transparent, and benefits can be difficult to quantify. In addition, these conversations have limited benefit to patients who cannot afford even the lowest tier of care. Other barriers to practice-based approaches include staff shortages and the inherent conflict of interest driven by higher revenues from high-cost oncology drugs.

The authors suggest the path to alleviating the financial toxicity of cancer care is a coordinated national policy approach. Beyond drug price legislation, other critical policies are those related to insurance coverage options, flexible work schedules, paid sick leave, financial planning assistance, and limits on out-of-pocket spending relative to household income and assets. Many prescription drugs do not have an annual out-of-pocket cap, and some health plans have deductibles higher than some patients can afford. These patients need support not only for their care, but also to help provide for their daily needs beyond insurance for treatment. The Affordable Care Act has helped to expand coverage options, but implementation at the state level is inconsistent. The best way to ensure continued progress will be for multiple stakeholders to raise awareness of the devastation of financial toxicity and demand bold actions from policy makers.

High Level
Practice-based approaches, such as decision-support tools, may help close gaps in fiscal protection, but ultimately will require financial and technical support, as well as coordination to ensure success. If implemented, some level of funding and reimbursement would be required for these approaches to be both successful and sustainable. Policy makers need to establish strategies that close the disparities between financially secure and financially disadvantaged patients and help protect patients from high out-of-pocket costs. There is an immediate need for policies that address access to care, high healthcare costs, absence of paid medical leave, and other gaps. The resulting broader healthcare coverage could have important economic benefits, such as increased labor force participation and lower costs to small businesses.

Ground Level
Dr Bradley and colleagues suggested that despite potential barriers, practice-level financial screening and mitigation – with associated reimbursement – are still an appropriate part of routine care. Especially in the short term, practice-based approaches remain important because existing policies may fall short of sheltering patients and their families from the financial toxicities of cancer care.

Therapeutic Area

Archives

Matthew Gordon

VP, Real-World Evidence
Matthew has more than 25 years of experience in real-world evidence and observational, non-interventional research. He has led studies across the full life cycle—from startup through publication—supporting objectives that range from understanding a disease’s natural history to fulfilling global safety surveillance requirements. Matthew brings deep expertise in orphan disease programs, having overseen more than 25 long-term, global initiatives, as well as in disease and product registries, prospective pharmacoeconomic studies, and systematic literature reviews. Matthew leads the RWE Registries team, responsible for building the business and team. Prior to joining Aptitude Health, he held senior leadership roles at Parexel, Worldwide Clinical Trials, inVentiv Health Clinical, Quintiles Outcome, and ICON Clinical Research. Matthew holds a BA in sociology from Boston University, is a long-standing member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a frequent speaker at ISPOR, the Center for Business Intelligence, and related industry conferences.

Gerald Stanvitch, PhD

VP, Scientific Content

Cate Browning, PhD

VP, Global Medical Affairs

Erin Zingales Rau

VP, Account Services

Kelly Kocor

VP, People & Culture
Kelly leads both the human resources and talent acquisition teams, ensuring that Aptitude Health attracts, retains, and develops top personnel to drive our continued success. With over 17 years of experience transforming global HR initiatives, Kelly is an expert in harmonizing HR policies and fostering a culture of engagement and partnership. She is committed to partnering with all areas of the business to ensure full regulatory compliance and delivering value-added services to our organization and its people. Kelly is passionate about developing and implementing HR strategies that help support our employees’ professional and personal growth. She is dedicated to fostering a culture that encourages innovation, collaboration, and inclusivity, helping Aptitude Health continue to be a great place to work.

Bart Zygmond

VP, Finance
Bart brings a wealth of experience to the organization, having worked in the life sciences, pharmaceuticals, manufacturing, and service industries. With his expertise in financial reporting, US GAAP, SOX, cash flow modeling, and financial analysis, he plays a crucial role in the company’s financial management and strategy. Prior to joining Aptitude Health as VP, Finance, Bart held several controller positions: at Q2 Solutions, he oversaw the global finance team and financial operations, ensuring the accurate and timely financial reporting of the company. He also held controller positions at Domtar Inc and Veristat.

Eugene Vissers, MD

Senior VP, Global Scientific Content
Eugene is a seasoned medical doctor with over 20 years of international experience in pharma, consultancy, and agency environments. Eugene leads the US team of dedicated experts responsible for developing high-quality medical content. Prior to joining Aptitude Health, Eugene served as medical director at Ipsen and AstraZeneca. With both his medical degree and an MBA, Eugene brings a unique perspective to his role. His clinical background, combined with his business acumen, allows him to develop innovative strategies that drive results. Under Eugene’s leadership, the medical content team delivers scientific information of the highest quality, providing valuable insights to our clients around the world.

Adrian Barfield

VP, US Business Development

Kelley Hernandez

Executive VP, US Business Development
Kelley has over 18 years of experience in the oncology space. Kelley joined Aptitude Health after working with Cardinal Health, where she was part of the Healthcare and Analytics Division, and finished her tenure there with VitalSource™ (GPO division). As the leader of the strategic business development team for the US, Kelley brings a wealth of expertise to the organization. Her experience in the healthcare industry, combined with her ability to identify and capitalize on new business opportunities, is invaluable in driving the company’s growth and success. Kelley’s dedication to building strong relationships with life science partners is a testament to her commitment to delivering exceptional value to the healthcare industry.

Adam Sinensky, MBA

Chief Technology Officer

Adam has over 20 years of experience in the healthcare industry and an MBA in healthcare management. After 10 years as a strategy consultant to life science companies, Adam has spent the last decade as a product and strategy leader focused on bringing technology products to market across the payor, provider, and life sciences segments. By combining his business acumen and experience working directly with software developers, engineers, and data scientists, Adam has successfully led numerous product launches and enhancements from ideation to development and go-to-market initiatives. His product and change management expertise has led organizational shifts from services to technology at companies such as Change Healthcare and Datavant/Ciox. At Aptitude Health, Adam is responsible for growing our portfolio of product offerings by leveraging real-world data and artificial intelligence with our existing solutions and industry-leading Axess Network of healthcare providers. He also oversees our IT and cybersecurity teams.

Stefanie Daniels

Chief Commercial Officer

Stefanie is a seasoned healthcare executive with over 20 years of experience in oncology. She brings a wealth of knowledge and expertise to the organization. Stefanie joined Aptitude Health after spending over a decade as a senior director at Physicians’ Education Resource, an oncology CME vendor. During her tenure, she led and managed teams responsible for grant development/acquisition, program creation/execution, and faculty management. Stefanie’s deep understanding of the oncology industry and her ability to lead teams through complex projects make her a vital part of the organization’s success. Her dedication to providing high-quality solutions to our life science partners is a testament to her commitment to improving cancer patient care.

Jason Cash

Chief Financial Officer

Jason is an accomplished finance professional with over 20 years of experience in the pharmaceutical services industry. Throughout his career, he has demonstrated a keen ability to navigate high-growth organizations, delivering exceptional results. Before joining Aptitude Health, Jason served as the CFO of Veristat International, a global contract research organization. In this role, he led the financial strategy and played a pivotal role in driving the company’s growth and success. Jason’s wealth of experience and expertise in financial management make him an essential member of the leadership team. His strategic thinking and ability to drive results are highly respected within the industry.

Jez Moulding

Chief Executive Officer
Jez is a seasoned leader with over 20 years of experience in general management and regional president roles. He has a proven track record of success in the healthcare industry, having worked in the US, Japan, Australia, Korea, South Africa, France, and the UK for Sanofi, where he supported the launch of 10 new drugs across various therapeutic areas. As chief commercial officer at UDG Healthcare and EVP at Ashfield, Jez demonstrated his expertise in developing and implementing successful business strategies. He joined Aptitude Health from Pharmaspectra, an IQVIA business, where he served as CEO since 2018. Jez’s extensive experience in the pharmaceutical industry and his leadership skills make him an invaluable asset to the organization.
Aptitude Health
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.